skip to main content

Paternal valproate exposure — DFSRH MCQ

Instant feedback + full explanation. One question, done properly.

EasyTeratogenicityPaternal valproate exposureDFSRH

On 19 August 2026, a 34-year-old woman attends for preconception advice. She has a copper intrauterine device in situ. Her male partner was taking sodium valproate for generalised epilepsy but, following specialist review, completed a supervised switch to levetiracetam and took his final valproate dose on 8 July 2026. He remains seizure-free. They wish to conceive as soon as reasonably possible and ask when her intrauterine device should be removed. Which is the most appropriate plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Retain the copper intrauterine device and defer conception until 8 October 2026

Current MHRA and FSRH precautionary advice is that men exposed to valproate and their female sexual partners should use effective contraception during treatment and for at least 3 months after the final dose. This permits completion of a sperm cycle without valproate exposure. As his final dose was on 8 July 2026, conception should be deferred until 8 October 2026. The copper intrauterine device is already highly effective contraception, so it should remain in situ until the precautionary interval has elapsed; condoms are not additionally required purely for pregnancy prevention while a highly effective method is being used. B preserves the correct conception date but unnecessarily replaces highly effective contraception with a method having a higher typical-use failure rate. C allows only 2 months after cessation. D disregards the paternal exposure window. E imposes a 6-month interval, which is not required for valproate. The underlying evidence is a retrospective observational study: pooled data suggested more neurodevelopmental disorders following paternal valproate exposure around conception than following lamotrigine or levetiracetam exposure, but causality is unconfirmed. The recommendation is therefore precautionary rather than proof of direct teratogenesis; seminal transfer is considered unlikely, with germ-cell genetic or epigenetic effects remaining possible mechanisms.

Reference: FSRH Statement: Paternal exposure to valproate and the risk of neurodevelopmental disorders in children (September 2024) — https://www.fsrh.org/Common/Uploaded%20files/documents/fsrh-statement-paternal-exposure-to-valproate.pdf Valproate use in men: as a precaution, men and their partners should use effective contraception (Published 5 September 2024; post-publication updates through June 2025) — https://www.gov.uk/drug-safety-update/valproate-use-in-men-as-a-precaution-men-and-their-partners-should-use-effective-contraception